APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Listen to our experts summarise the safety profile of OFEV® in INBUILD®
Document ID: PC-MY-101522
22/03/2021
Author: Boehringer Ingelheim
RELATED CONTENT
PC-MY-101522
Production date: March 2021
Production date: March 2021